ClinicalTrials.gg
WithdrawnNCT05985876KULEA-NETUpdated Oct 16, 2026

KULEA-NET: A Mobile Application for African American/Black Mothers to Promote Exclusive and Continuous Breastfeeding

An interventional study of KULEA-NET application and Control Group: Usual Care in Breastfeeding and Exclusive Breastfeeding, sponsored by Benten Technologies, Inc.. Withdrawn at 3 sites in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Benten Technologies, Inc. · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
Lapse in SBIR reauthorization and lack of funding
Updated Oct 16, 2026Now WithdrawnStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Breast Feeding with a site in United States — 43 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.

Enrollment
189th of 202
0 · median 83
Started
2025
with 15 others
No phase
164 of 251
26 open now
Registered
196th of 251
by date

Among the 251 studies in Breast Feeding with a site in United States, this one is the 189th largest by enrollment of the 202 interventional ones that give a count, is one of 16 that started in 2025, is one of 164 with no phase, and was the 196th registered.

Breast Feeding

1,083 studies on the registry are indexed under Breast Feeding; 216 are open to participants now.

Browse Breast Feeding studies →

Open to participants now

43 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Breast Feeding studies recruiting now, 65 (52%) set no upper age limit and 58 (46%) stop at 75 or younger; 52 take children under 18; 75 take healthy volunteers.

This study: 18 Years to 44 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Breast Feeding with a site in United States, or all of them as a file.
02

Study summary

KULEA-NET is a mHealth intervention that will improve knowledge, self-efficacy, and intentions related to exclusive breastfeeding (EBF). These factors have been demonstrated to have a positive influence on breastfeeding (BF) initiation and duration among African American/Black (AA/B) mothers. In the long term, KULEA-NET has great potential to achieve increased BF initiation and EBF rates among AA/B mothers and as a result, improved maternal and infant health outcomes.

Read the detailed description

Failure to initiate breastfeeding (BF) and exclusively breastfeed (EBF) for the recommended 6-month duration, can result in long-term morbidity among both mothers and their infants. African Americans/Blacks (AA/B) have the lowest BF initiation and EBF rates among all racial ethnicities in the US. AA/B infants have disproportionately high rates of mortality, and children have a high incidence of asthma and sudden infant death syndrome (SIDS) while AA/B mothers are at high risk for chronic illnesses like obesity, diabetes, and cardiovascular diseases. These health disparities cost the US more than $9.1 billion in medical treatment annually but can be reduced by increasing EBF rates. However, AA/B women experience barriers on multiple levels to initiating, continuing BF, and maintaining EBF (either by discontinuing BF or introducing supplements BF with other foods). With high rates of smartphone ownership and consumption of digital content in AA/B women, the proposed mHealth intervention has great potential to increase BF initiation and maintain EBF among AA/B women and has demonstrated feasibility (user satisfaction and use) in our prior completed feasibility study. The proposed SBIR Direct Phase II application, Knowledge and Usage of Lactation using Education and Advice from Support Network (KULEA-NET) addresses an unmet need for an evidence-based mobile app, providing comprehensive BF support and addresses the interrelated and complex BF barriers AA/B mothers experience across the socio-ecological layers.

KULEA-NET will provide comprehensive BF support to nurture and support AA/B women in BF initiation and EBF, and include the following innovative features: a) Social marketing and health branding to promote EBF as a socially desirable behavior; b) Micro-learning educational content to improve the acquisition of knowledge and skills related to EBF; c) Support network communication tools leveraging asynchronous communication that allow mothers to communicate with her BF supporters, peers, and lactation professional supports; d) Context-aware delivery framework that will capitalize on user information such as date of delivery, feeding, and diaper log data, and location variables to provide timely feedback, content, and guidance; and e) a Virtual community support network bringing together AA/B mothers and their spouse/family members, and fostering a community of mutual support.

The hypothesize of KULEA-NET is to improve knowledge, BF self-efficacy, and intentions to BF, and ultimately achieve increased BF initiation, BF duration, and EBF rates at 6 months among AA/B mothers and, as a result, improved maternal and infant health outcomes.

03

Conditions studied

  • Breastfeeding
  • Exclusive Breastfeeding

Browse trials for

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • African American/Black Ethnicity
  • Speak and understand English,
  • Between the ages of 18-44 years,
  • Intention to continue BF after discharge from the hospital
  • Willingly provide written
  • Own a smartphone (either iOS or Android)
  • Have access to the internet through their smartphone

Exclusion criteria

Exclusion Criteria:

  • An infant born with cleft lip/palate, congenital heart defects, Down Syndrome, neural tube defects, or other conditions that require admission to a NICU or interfere with BF
  • (HIV)
  • Taking antiretroviral medication or chemotherapy agents
  • Untreated, active tuberculosis
  • T-Cell lymphotropic virus type I or type II
  • Illicit drug use
  • Receiving radiation therapy
  • Exposed to anthrax
  • Undergone breast surgery
  • Active or C
  • Any prescription drug use incompatible with lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    KULEA-NET application

    Participants using the KULEA-NET application in addition to the usual care

    Behavioral: KULEA-NET application

  • Experimental
    Control Group: Usual Care

    Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive the standard Babyscripts app only without the KULEA-NET tile.

    Behavioral: Control Group: Usual Care

Interventions

  • BehavioralKULEA-NET application

    African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.

  • BehavioralControl Group: Usual Care

    Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).

06

What researchers measure

Primary outcomes

  1. Change of exclusive breastfeeding (EBF) rates

    We will assess if participants are breastfeeding exclusively through self-reported information and corroborate with data entered in the feeding and diaper logs. We will record information on EBF at 4 weeks, and 24 weeks follow-up among women in the intervention arm #1. We will record information on EBF at 4 weeks, and 24 weeks follow-up among women in the intervention arm #2. We will record information on EBF at baseline, 4 weeks, and 24 weeks follow-up among women in the intervention arm #3.

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

Secondary outcomes

  1. Change of any breastfeeding (BF) rates

    We will assess if participants are breastfeeding through self-reported information and corroborate with data entered in the feeding and diaper logs. We will record information on BF at 4 weeks, and 24 weeks follow-up among women in the intervention arm #1. We will record information on BF at 4 weeks, and 24 weeks follow-up among women in the intervention arm #2. We will record information on EBF at baseline, 4 weeks, and 24 weeks follow-up among women in the intervention arm #3.

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

  2. Change of breastfeeding initiation rates

    We will assess if participants are initiated breastfeeding through self-reported information and corroborate with data entered in the feeding and diaper logs. We will record information on BF initiation at baseline, 4 weeks, and 24 weeks follow-up among women in the intervention arm.

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

Other outcomes

  1. Change of breastfeeding attitudes

    Iowa Infant Feeding Attitude Scale (IIFAS)

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

  2. Change of intention to breastfeed

    Infant Feeding Intentions (IFI) Scale

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

  3. Change of breastfeeding self-efficacy

    BF Self-Efficacy Scale Short Form (BSES-SF)

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

  4. Change of perceived social support and social self-efficacy

    Interpersonal Support Evaluation List (ISEL)

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

  5. Usability

    System Usability Scale (SUS)survey will be used to assess usability of the KULEA-NET app

    Time frame: Week 24 postpartum

  6. Engagement

    Brand Equity Scale to measure engagement with the app

    Time frame: Week 24 postpartum

  7. Change of knowledge and beliefs about breastfeeding

    Custom survey, based in part on an instrument developed by Dr. Evans and colleagues to evaluate the KULEA-NET intervention (GWU IRB approval # 111047), will be used to collect self-reported knowledge and attitudes related to breastfeeding.

    Time frame: Baseline, week 4 postpartum follow-up and week 24 postpartum follow-up

07

Study locations

3 sites
  • Mamatoto Village
    Washington D.C., District of Columbia 20019-3739, United States
  • The George Washington University
    Washington D.C., District of Columbia 20052-0042, United States
  • Medstar Health Research Institute
    Hyattsville, Maryland 20782, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Jun 2025, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Nov 2023 → Jun 2025, primary completion Apr 2024 → Jun 2025 and completion May 2024 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Aug 14, 2023
StartActual
Jun 30, 2025was Nov 2023
Primary completionActual
Jun 30, 2025was Apr 2024
CompletionActual
Jun 30, 2025was May 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Withdrawn Lapse in SBIR reauthorization and lack of funding
changed Oct 16, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Mamatoto Village · Washington D.C., United States
  • The George Washington University · Washington D.C., United States
Show 2 removed
  • Mamatoto Village · Washington, United States
  • The George Washington University · Washington, United States
Oct 16, 2026
Start date
Nov 1, 2023→Jun 30, 2025 (actual)
Oct 16, 2026
Primary completion
Apr 30, 2024→Jun 30, 2025 (actual)
Oct 16, 2026
Study completion
May 30, 2024→Jun 30, 2025 (actual)
Oct 16, 2026
Enrollment
523 (estimated)→0 (actual)
Oct 16, 2026
Design
Phase 2→Not applicable
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Enrolling by invitation→Withdrawn
    Why stopped Lapse in SBIR reauthorization and lack of funding
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Mamatoto Village · Washington D.C., United States
    • The George Washington University · Washington D.C., United States
    Show 2 removed
    • Mamatoto Village · Washington, United States
    • The George Washington University · Washington, United States
    Start date Nov 1, 2023→Jun 30, 2025 (now actual)
    Primary completion Apr 30, 2024→Jun 30, 2025 (now actual)
    Study completion May 30, 2024→Jun 30, 2025 (now actual)
    Enrollment 523 (estimated)→0 (actual)
    Design Phase 2→Not applicable
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05985876
Lead sponsor
Benten Technologies, Inc.
Responsible party
Tony Ma (Project Director or Principal Investigator, Benten Technologies, Inc.) — Principal investigator
First posted
Aug 14, 2023
Start date
Jun 30, 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Oct 16, 2026

Study contacts

Tony Ma, MS
principal investigator · Benten Technologies
Doug Evans, PhD
principal investigator · George Washington University
Loral Patchen, PhD
principal investigator · Medstar Research Health Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion